Clinical Trials
22 trialsNCT05311618 2024-04-01
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Phase 1 Unknown
NCT05278975 2024-01-26
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
RS Oncology LLC
Phase 1/2 Unknown
NCT04670445 2023-10-23
UPLIFT
Massachusetts General Hospital
Phase NA Unknown
NCT06010277 2023-08-24
FLEX
Amphia Hospital
Phase 4 Unknown
NCT04631731 2023-06-01
ICEMELT
Western Sydney Local Health District
Phase 1/2 Unknown
NCT04940637 2023-05-12
UNITO-001
University of Turin, Italy
Phase 2 Unknown
NCT05415098 2022-11-16
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
Ascentage Pharma Group Inc.
Phase 1 Unknown
NCT02637531 2022-04-04
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
Infinity Pharmaceuticals, Inc.
Phase 1 Unknown
NCT04804410 2021-03-18
Dielectric Properties of Matched Tissue Samples From Thoracic Malignancies and Corresponding Normal Tissues
University of Maryland, Baltimore
Phase NA Unknown
NCT04489862 2020-07-28
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Unknown
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT02040272 2019-10-30
MARS2
Royal Brompton & Harefield NHS Foundation Trust
Phase NA Unknown
NCT02349958 2019-04-16
HIPEC/IPHC
Bay Area Gynecology Oncology
Phase 2 Unknown
NCT02758587 2018-03-19
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
NHS Greater Glasgow and Clyde
Phase 1/2 Unknown
NCT02395679 2015-03-23
MesoCancerVa
Erasmus Medical Center
Phase 1 Unknown
NCT01569919 2013-03-12
SKOPOS
Wales Cancer Trials Unit
Phase 2 Unknown
NCT00996385 2011-10-31
Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
Columbia University
Phase 2 Unknown
NCT01281800 2011-01-24
AGILI
Institute of Oncology Ljubljana
Phase 2 Unknown
NCT00794859 2009-08-04
SMS
King's College London
Phase 2 Unknown
NCT00454519 2009-02-13
IPHC
Wuhan University
Phase 2 Unknown
NCT00685204 2008-05-28
TL139
Taxolog Inc.
Phase 2 Unknown
NCT00551252 2007-10-30
A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma
Gruppo Italiano MEsotelioma
Phase 2 Unknown